ClinicalTrials.gg

Program

trifarotene

Also written as “Trifarotene”, “Trifarotene Cream 0.005%” and “Trifarotene Cream”.

Its studies are mostly in Acne Vulgaris · Ichthyosis, Lamellar, led by 4 companies.

Furthest: phase 4, since Jun 25, 202013 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galderma Group91 open or runningphase 4since Jun 25, 2020Jun 8, 2012Dec 31, 2026phase 3 · NCT07186413
Sun Pharmaceutical Industries20 open or runningphase 1since Sep 20, 2023Sep 20, 2023none ahead
Mayne Pharma International Pty10 open or runningphase 2since Oct 24, 2018Oct 24, 2018none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Sep 19, 2022Sep 19, 2022none ahead

Also a collaborator on its studies: teva-pharmaceuticals-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 8, 2012First study: phase 2 study in Acne VulgarisNew to Galderma GroupGalderma Group · NCT01616654 · 304 enrolled · United States
  2. Jul 11, 2014Phase 3 study in Acne VulgarisGalderma Group · NCT02189629 · 453 enrolled · United States, Czechia, Germany and more
  3. Sep 18, 2015Phase 3 study in Acne VulgarisGalderma Group · NCT02556788 · 1,212 enrolled · United States, Czechia, Hungary and more
  4. Oct 1, 2015Phase 3 study in Acne VulgarisGalderma Group · NCT02566369 · 1,208 enrolled · United States, Canada, Germany and more
  5. Oct 24, 2018Mayne Pharma International Pty's first study: phase 2 study in Ichthyosis, LamellarNew to Mayne Pharma International PtyMayne Pharma International Pty · NCT03738800 · 65 enrolled · United States, Australia, Canada and more
  6. Apr 12, 2019Phase 3 study in Acne VulgarisGalderma Group · NCT03915860 · 47 enrolled · United States
  7. Jun 25, 2020Phase 4 study in Acne VulgarisGalderma Group · NCT04451330 · 202 enrolled · United States, Puerto Rico
  8. Apr 20, 2021Phase 4 study in Acne VulgarisGalderma Group · NCT04856904 · 121 enrolled · United States, Canada, France
  9. Oct 11, 2021Phase 4 study in Acne VulgarisGalderma Group · NCT05089708 · 123 enrolled · United States, Spain
  10. Sep 19, 2022Teva Pharmaceutical Industries's first study: phase 3 study in Acne VulgarisNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT05550337 · 807 enrolled · United States
  11. Sep 20, 2023Sun Pharmaceutical Industries's first study: phase 1 study in Acne VulgarisNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT06063473 · 762 enrolled · United States
  12. Dec 10, 2024Phase 1 study in Acne VulgarisSun Pharmaceutical Industries · NCT06733402 · 1,000 enrolled · United States
  13. Aug 26, 2025Phase 3 study in Acne VulgarisGalderma Group · NCT07186413 · 561 enrolled · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Acne VulgarisGalderma Group · NCT07186413

TargetBeta

RARG →read by rule
“Retinoic acid receptor gamma agonist”ChEMBL 37, by rule

Other programs on RARG

ProgramCompanyFurthest phaseStudies
PalovaroteneruleIpsenphase 310

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07186413Acne Vulgaris · China3Active, not recruitingGalderma GroupDec 31, 2026561
NCT06733402Acne Vulgaris · United States1CompletedSun Pharmaceutical IndustriesJun 20, 20241,000
NCT06063473Acne Vulgaris · United States1CompletedSun Pharmaceutical IndustriesJul 13, 2023762
NCT05550337Acne Vulgaris · United States3CompletedTeva Pharmaceutical IndustriesMay 9, 2023807
NCT05089708Acne Vulgaris · United States, Spain4CompletedGalderma GroupDec 15, 2022123
NCT04856904Acne Vulgaris · United States, Canada, France4CompletedGalderma GroupFeb 8, 2023121
NCT04451330Acne Vulgaris · United States, Puerto Rico4CompletedGalderma GroupApr 26, 2021202
NCT03915860Acne Vulgaris · United States3CompletedGalderma GroupDec 23, 201947
NCT03738800Ichthyosis, Lamellar · United States, Australia, Canada and more2TerminatedMayne Pharma International PtySep 3, 202165
NCT02566369Acne Vulgaris · United States, Canada, Germany and more3CompletedGalderma GroupNov 14, 20171,208
NCT02556788Acne Vulgaris · United States, Czechia, Hungary and more3CompletedGalderma GroupFeb 7, 20171,212
NCT02189629Acne Vulgaris · United States, Czechia, Germany and more3CompletedGalderma GroupFeb 23, 2017453
NCT01616654Acne Vulgaris · United States2CompletedGalderma GroupJul 24, 2013304

How it is read

Names in the registry

  • “Trifarotene”, 2 entries
  • “Trifarotene Cream 0.005%”, 2 entries
  • “Trifarotene Cream”, 2 entries
  • “Trifarotene 0.005 % Topical Cream”, 1 entry
  • “CD5789 Cream 200 µg/g”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.